PACB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient trader. PACB is trading ~$2.34 pre-market (below the ~$2.42 pivot), with no Intellectia buy signals, elevated options-implied risk into the Feb 12 earnings event, and Wall Street price targets clustered around ~$2 (i.e., limited upside vs. the current price). I would wait for either a dip closer to ~$2.18–$2.03 support or a clean reclaim of ~$2.42 with momentum before buying; as of now, the risk/reward is unfavorable for an immediate entry.
Trend/Structure: Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), implying the broader trend has turned up. However, pre-market price (~2.34) is below the pivot (2.421), suggesting near-term momentum is not yet confirmed. Momentum: MACD histogram is positive (0.0177) but “positively contracting,” which often signals the upswing is losing steam rather than accelerating. RSI_6 ~47.8 is neutral—no oversold bounce signal. Key levels: Immediate decision area is the pivot at ~2.421. Resistance levels: R1 ~2.665 then R2 ~2.817. Support levels: S1 ~2.177 then S2 ~2.025. With price below pivot, downside tests of S1/S2 are plausible. Pattern-based forward bias: Similar candlestick-pattern cohort implies ~60% chance of ~-0.22% next day, ~+0.87% next week, ~+5.73% next month—mildly positive longer horizon, not compelling for a “buy-now” impatient entry.
Intellectia Proprietary Trading Signals
Pattern-based model suggests modestly positive 1-month drift (+5.73%).
Revio placements declined to 21 units, potentially pressuring the high-end platform narrative. Shares are already above the most recently cited $2 price targets, limiting near-term upside vs consensus. Earnings on 2026-02-12 (after hours) with very high IV increases event-driven downside risk. Technicals show weakening momentum (MACD contracting) and price is below pivot resistance (~2.421). No supportive insider/hedge fund trend signals; no politician/congress buy signals present.
Latest reported quarter: 2025/Q3. Revenue fell to ~$38.44M (-3.82% YoY). Net income was more negative (-$38.0M; -37.42% YoY) and EPS declined to -0.13 (-40.91% YoY), indicating losses deepened. A notable bright spot is gross margin, which improved to ~50.84% (large YoY improvement), suggesting better mix/efficiency, but profitability is still far off. For the upcoming 2025/Q4 print (Feb 12), prelim revenue implies re-acceleration (+14% YoY), which is constructive if confirmed with better instrument/consumables outlook.
Recent trend: Analysts have been lifting price targets modestly (Barclays $1.50→$2 Equal Weight; Piper $1.50→$2 Neutral; Stephens $1.80→$2 Overweight). Ratings remain mixed/mostly cautious (Neutral/Equal Weight) with one bullish (Overweight). Wall Street pros: expectation of improving end markets into 2026; potential upside from Revio utilization/consumables; NIH clarity could help instrument demand. Wall Street cons: recent quarter missed expectations per Stephens commentary; visibility remains uneven (Revio placements down), and targets cluster around $2—below/near the current price—implying limited conviction in near-term upside from here.
